PharmaTher and Craft Health Build 3D Platform for Personalized Peptides

PharmaTher Launches Dedicated Personalized Peptide Division

Toronto-based PharmaTher Holdings Ltd. has formed a new division called Personaliz3D Peptides with a clear goal: use 3D printing to produce peptide medicines tailored to individual patients. The company followed up that announcement two days later by naming its manufacturing partner, Singapore-based Craft Health Pte. Ltd., and the system it intends to use: the CraftMake pharmaceutical 3D printer.

The collaboration is focused on developing formulations for six specific peptides. BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax are the compounds under evaluation. These happen to be the same six peptides that the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee recently recommended for inclusion on the Section 503A Bulks List. The recommendation is advisory and not binding, but it signals genuine regulatory movement toward a clearer framework for compounded peptide medicines in the United States.

How CraftMake Prints Peptide Doses

CraftMake uses semi-solid paste extrusion. It deposits material at room temperature with no heat and no UV curing involved. That approach matters for peptides, which can degrade at high temperatures. The printer supports single-material builds, multi-material builds, and pill-in-pill configurations. That last option is how a manufacturer could put a taste-masking coating around a peptide core, or design a dose that releases in two stages.

Craft Health's GMP-oriented configuration, called CraftMake Production Plus, adds an enclosed printing environment and dual printheads that deposit two materials at the same time. The company quotes a dosing accuracy of approximately plus or minus one percent and repeatability above 99 percent.

The hardware runs CraftControl software to manage print workflows, and CraftBlends, Craft Health's library of proprietary printable formulations, covers immediate, delayed, sustained-release, and orally disintegrating profiles.

Why Peptide Personalization Is Hard Right Now

Most peptide compounding today uses fixed doses in injectable or liquid formats. That model works for broad patient populations, but it leaves little room for individual adjustment. Patients on peptides for tissue repair, inflammation, or hormone regulation often need different doses at different stages of treatment. Personalized manufacturing could let pharmacies adjust the dose, combine multiple peptides in a single unit, or control how quickly the active ingredients release inside the body.

Market analysts at Future Market Insights expect the global 3D printed drugs market to grow from roughly 435.8 million dollars in 2026 to 1.1 billion dollars by 2036, at a 9.8 percent compound annual growth rate. Pharmaceutical 3D printing has been the backbone of that projection, and the PharmaTher-Craft Health deal is a concrete example of the trend moving from research labs toward regulated, on-demand production.

What Happens Next

PharmaTher and Craft Health plan to test the six recommended peptides across oral thin films and gummy formats, among other dosage designs. PharmaTher also intends to explore a broader commercial arrangement that could place CraftMake systems inside qualified Section 503A compounding pharmacies. For the additive manufacturing industry, the collaboration signals that extrusion-based 3D printing is finding a practical home in regulated pharmaceutical manufacturing, beyond the tablet-printing pilot projects that have dominated the category so far.